A Phase 1/2 interventional study of INH 69 U (low) and INH 69 U (high) in Type 2 Diabetes Mellitus, sponsored by Dance Biopharm Inc.. Completed. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2016-03-23.
Sponsored by Dance Biopharm Inc. · Phase 1/2 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Pharmacokinetic (PK) and Pharmacodynamic (PD) dose-response investigation of Dance-501 inhaled human insulin
This study investigated the pharmacokinetic (PK) and pharmacodynamic (PD) properties of Dance-501, a novel inhaled human insulin liquid formulation (INH) and device. Twenty-four subjects with type 2 diabetes (T2DM) received 3 INH doses: low (69 units), medium (139 units) and high (208 units) and 1 equivalent medium dose (18 units) of subcutaneous insulin lispro (LIS).
The medium dose was repeated to determine within subject variability. PD was investigated during a 12 hour euglycemic clamp.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 24 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Dance Biopharm Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
single 69 U dose administration of Dance inhaled human insulin using a low-concentration formulation (300 U/mL)
Drug: INH 69 U (low)
single 69 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL)
Drug: INH 69 U (high)
single 139 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL) This arm was repeated in order to evaluate intra-subject variability.
Drug: INH 139 U
single 208 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL)
Drug: INH 208 U
single 18 U dose administration of subcutaneous insulin lispro using a 100 U/mL formulation This arm was repeated in order to evaluate intra-subject variability.
Drug: LIS 18 U
inhaled human insulin
Also known as: Dance-501
inhaled human insulin
Also known as: Dance-501
inhaled human insulin
Also known as: Dance-501
inhaled human insulin
Also known as: Dance-501
subcutaneous insulin lispro
Also known as: subcutaneous insulin lispro
Area under the curve for insulin from 0-8 hours (AUCins0-8h)
Assessment of the linearity of the dose-response curves
Time frame: 0 to 8 hours following each dose
Maximum concentration of insulin (CMaxIns)
Assessment of the linearity of the dose-response curves
Time frame: up to 12 hours following each dose
Area under the curve for glucose infusion rate from 0-12 hours (AUGgir0-12h)
Assessment of the linearity of the dose-response curves
Time frame: 0 to 8 hours following each dose
Maximum glucose infusion rate (GIRmax)
Assessment of the linearity of the dose-response curves
Time frame: up to 12 hours following each dose
Bioavailability
Relative delivery efficiency (FREL) of inhaled human insulin (INH) compared to subcutaneous injected insulin lispro (LIS)
Time frame: 0 to 8 hours following each dose
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Oct 2013, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dance Biopharm Inc.